참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Ammonium Hydroxide | HCID 14923 | — |
| 반응물 | Sodium hydride | HCID 24758 | — |
| 반응물 | 1-(3-Isopropyl-1,2,4-oxadiazol-5-YL)piperidin-4-OL | HCID 21897744 | — |
| 반응물 | 7-(2-Fluoro-4-methanesulfonyl-phenyl)-4-methanesulfonyl-thieno[3,2-d]pyrimidine | HCID 68299280 | — |
| 용매 | Dimethylformamide | HCID 6228 | — |
| 생성물 | GPR119 agonist 2 | HCID 86699298 | 59.7% |
반응 단계
1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-ol (30 mg) was dissolved in N,N-dimethylformamide (2 mL) and cooled to an internal temperature of 0° C. Then, NaH (9 mg) was slowly added thereto and stirred for 30 min. 7-(2-fluoro-4-methanesulfonyl-phenyl)-4-methanesulfonyl-thieno[3,2-d]pyrimidine (50 mg) synthesized in Preparation Example 2 was slowly added thereto and heated to room temperature, followed by stirring for 2 hours. Then, the reaction mixture was mixed with a saturated solution of ammonium hydroxide, and extracted twice with ethyl acetate. The organic layer thus obtained was washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain a foamy residue. The residue was crystallized in the presence of diethyl ether to obtain the title compound (40 mg) as a whitish solid.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US08853213B2 |
|---|
| 출처 데이터셋 | uspto-grants-2014_10 |
|---|
| ORD ID | ord-a6374645a9fd4d26a7e8ae902fa7a44a |
|---|
| 출처 메모 | uspto-grants-2014_10 |
|---|